The estimated Net Worth of Fredric N Eshelman Ventures... is at least 368 千$ dollars as of 1 April 2022. Fredric Ventures owns over 4,545,455 units of Aravive Inc stock worth over 368,471$ and over the last 4 years Fredric sold ARAV stock worth over 0$.
Fredric has made over 1 trades of the Aravive Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Fredric exercised 4,545,455 units of ARAV stock worth 181,818$ on 1 April 2022.
The largest trade Fredric's ever made was exercising 4,545,455 units of Aravive Inc stock on 1 April 2022 worth over 181,818$. On average, Fredric trades about 505,051 units every 0 days since 2020. As of 1 April 2022 Fredric still owns at least 9,211,769 units of Aravive Inc stock.
You can see the complete history of Fredric Ventures stock trades at the bottom of the page.
Over the last 6 years, insiders at Aravive Inc have traded over 107,045$ worth of Aravive Inc stock and bought 151,333 units worth 1,102,898$ . The most active insiders traders include Srinivas Akkaraju、Fredric N Eshelman Ventures...、Shahzad Malik. On average, Aravive Inc executives and independent directors trade stock every 75 days with the average trade being worth of 11,962$. The most recent stock trade was executed by Fredric N Eshelman Ventures... on 1 April 2022, trading 4,545,455 units of ARAV stock currently worth 181,818$.
versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.
Aravive Inc executives and other stock owners filed with the SEC include: